
<lom:lom xmlns:lom="https://oer-repo.uibk.ac.at/lom" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="https://oer-repo.uibk.ac.at/lom/latest https://w3id.org/oerbase/profiles/lomuibk/latest/schemas/lom-uibk.xsd">
  
<lom:general>
  
<lom:identifier>
  
<lom:catalog>phaidra.vetmeduni.ac.at</lom:catalog>

  
<lom:entry>
  
<lom:langstring xml:lang="x-none">o:2075</lom:langstring>

  
</lom:entry>

  
</lom:identifier>

  
<lom:identifier>
  
<lom:catalog>DOI</lom:catalog>

  
<lom:entry>
  
<lom:langstring xml:lang="x-none">10.1016/j.biopha.2022.113486</lom:langstring>

  
</lom:entry>

  
</lom:identifier>

  
<lom:title>
  
<lom:langstring xml:lang="en">The nature inspired peptide [T20K]-kalata B1 induces anti-tumor effects in anaplastic large cell lymphoma</lom:langstring>

  
</lom:title>

  
<lom:description>
  
<lom:langstring xml:lang="en">Ribosomally synthesized and post-translationally modified peptides, such as plant cyclotides, are a diverse group of natural products well known as templates in drug discovery and therapeutic lead development. The cyclotide kalata B1 (kB1) has previously been discovered as immunosuppressive agent on T-lymphocytes, and a synthetic version of this peptide, [T20K]kB1 (T20K), has been effective in reducing clinical symptoms, such as inflammation and demyelination, in a mouse model of multiple sclerosis. Based on its T-cell modulatory impact we studied the effects of T20K and several analogs on the proliferation of anaplastic large cell lymphoma (ALCL), a heterogeneous group of clinically aggressive diseases associated with poor prognosis. T20K, as a prototype drug candidate, induces apoptosis and a proliferation arrest in human lymphoma T-cell lines (SR786, Mac-2a and the Jurkat E6.1) in a concentration dependent fashion, at least partially via increased STAT5 and p53 signaling. In contrary to its effect on IL-2 signaling in lymphocytes, the cytokine levels are not altered in lymphoma cells. In vivo mouse experiments revealed a promising activity of T20K on these cancer cells including decreased tumor weight and increased apoptosis. This study opens novel avenues for developing cyclotide-based drug candidates for therapy of patients with ALCL.</lom:langstring>

  
</lom:description>

  
<lom:language>eng</lom:language>

  
<lom:keyword>
  
<lom:langstring xml:lang="en">Cyclotide Kalata B1; Peripheral T-Cell; Plant Cyclotides; Cycloviolacin O2; Tumor-Suppressor; Viola-Tricolor; Transcriptome; Mechanism; Products; Stat3</lom:langstring>

  
</lom:keyword>

  
</lom:general>

  
<lom:lifecycle>
  
<lom:datetime>2023-09-05T14:19:31.694Z</lom:datetime>

  
<lom:contribute>
  
<lom:role>
  
<lom:source>
  
<lom:langstring xml:lang="x-none">LOMv1.0</lom:langstring>

  
</lom:source>

  
<lom:value>
  
<lom:langstring xml:lang="x-none">Author</lom:langstring>

  
</lom:value>

  
</lom:role>

  
<lom:centity>
  
<lom:vcard>BEGIN:VCARD
VERSION:3.0
N:Lind;Judith;
FN:Judith Lind
END:VCARD</lom:vcard>

  
</lom:centity>

  
<lom:centity>
  
<lom:vcard>BEGIN:VCARD
VERSION:3.0
N:Kollmann;Karoline;
FN:Karoline Kollmann
X-ORCID:https://orcid.org/0000-0002-7937-4245
END:VCARD</lom:vcard>

  
</lom:centity>

  
<lom:centity>
  
<lom:vcard>BEGIN:VCARD
VERSION:3.0
N:Stoiber;Dagmar;
FN:Dagmar Stoiber
END:VCARD</lom:vcard>

  
</lom:centity>

  
<lom:centity>
  
<lom:vcard>BEGIN:VCARD
VERSION:3.0
N:Gruber;Christian W.;
FN:Christian W. Gruber
END:VCARD</lom:vcard>

  
</lom:centity>

  
<lom:centity>
  
<lom:vcard>BEGIN:VCARD
VERSION:3.0
N:Edtmayer;Sophie;
FN:Sophie Edtmayer
END:VCARD</lom:vcard>

  
</lom:centity>

  
<lom:centity>
  
<lom:vcard>BEGIN:VCARD
VERSION:3.0
N:Thell;Kathrin;
FN:Kathrin Thell
END:VCARD</lom:vcard>

  
</lom:centity>

  
<lom:centity>
  
<lom:vcard>BEGIN:VCARD
VERSION:3.0
N:Gattringer;Jasmin;
FN:Jasmin Gattringer
END:VCARD</lom:vcard>

  
</lom:centity>

  
<lom:centity>
  
<lom:vcard>BEGIN:VCARD
VERSION:3.0
N:Moll;Herwig P.;
FN:Herwig P. Moll
END:VCARD</lom:vcard>

  
</lom:centity>

  
<lom:centity>
  
<lom:vcard>BEGIN:VCARD
VERSION:3.0
N:Kudweis;Petra;
FN:Petra Kudweis
END:VCARD</lom:vcard>

  
</lom:centity>

  
<lom:centity>
  
<lom:vcard>BEGIN:VCARD
VERSION:3.0
N:Hellinger;Roland;
FN:Roland Hellinger
END:VCARD</lom:vcard>

  
</lom:centity>

  
</lom:contribute>

  
</lom:lifecycle>

  
<lom:educational>
  
<lom:learningresourcetype>
  
<lom:source>
  
<lom:langstring xml:lang="x-none">https://w3id.org/kim/hcrt/scheme</lom:langstring>

  
</lom:source>

  
<lom:id>https://w3id.org/kim/hcrt/text</lom:id>

  
<lom:entry>
  
<lom:langstring xml:lang="de">Textdokument</lom:langstring>

  
<lom:langstring xml:lang="en">Text</lom:langstring>

  
</lom:entry>

  
</lom:learningresourcetype>

  
</lom:educational>

  
<lom:rights>
  
<lom:copyrightandotherrestrictions>
  
<lom:source>
  
<lom:langstring xml:lang="x-none">LOMv1.0</lom:langstring>

  
</lom:source>

  
<lom:value>
  
<lom:langstring xml:lang="x-none">yes</lom:langstring>

  
</lom:value>

  
</lom:copyrightandotherrestrictions>

  
<lom:description>
  
<lom:langstring xml:lang="x-t-cc-url">https://creativecommons.org/licenses/by/4.0</lom:langstring>

  
</lom:description>

  
</lom:rights>

  
<lom:technical>
  
<lom:format>application/pdf</lom:format>

  
<lom:size>808560</lom:size>

  
<lom:location>https://phaidra.vetmeduni.ac.at/o:2075</lom:location>

  
<lom:thumbnail>
  
<lom:url>https://phaidra.vetmeduni.ac.at/api/object/o:2075/thumbnail</lom:url>

  
</lom:thumbnail>

  
</lom:technical>

  
<lom:classification>
  
<lom:purpose>
  
<lom:source>
  
<lom:langstring xml:lang="x-none">LOMv1.0</lom:langstring>

  
</lom:source>

  
<lom:value>
  
<lom:langstring xml:lang="x-none">discipline</lom:langstring>

  
</lom:value>

  
</lom:purpose>

  
</lom:classification>

  
</lom:lom>